Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Temporin L is a 13-amino acid antimicrobial peptide (AMP) originally isolated from the skin secretions of the European red frog, *Rana temporaria*. As a member of the temporin family, it is characterized by its small size, cationic nature, and amphipathic alpha-helical structure. Its primary mechanism of action involves the disruption of cell membranes through pore formation or a detergent-like effect, which leads to rapid cell lysis. While traditionally studied for its broad-spectrum antibacterial and antifungal properties, recent research has highlighted its potential as an antineoplastic agent. Specifically, Temporin L has shown significant in vitro anti-proliferative activity against marginal zone lymphoma (MZL) cell lines, maintaining efficacy even in models resistant to standard targeted therapies such as BTK, PI3K, and BCL2 inhibitors. It is currently being investigated by researchers at institutions including the Institute of Oncology Research and Sapienza University of Rome as a scaffold for developing novel lymphoma treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on temporin L.